

Subject Index

- Adhesion molecules—see also CD44 467, 549
- Anti-disialoganglioside monoclonal antibody 631
- Apoptosis 458, 463
- Ascorbic acid 463
- Bone marrow transplantation 572, 642
- C-MYC*—see *MYCN*
- CSRC* 435
- Calcyclin 499
- CD44 471, 541, 545, 549, 560
- Cell lines
 - ACN 527, 530
 - BE(2)M17 453, 486, 494, 591
 - CA-2-E 467
 - CHP 494, 616
 - CHRF-288-11 603
 - GI-CA-N 616
 - GI-ME-N 447, 467, 530
 - IMR-5 616
 - IMR-32 467, 471, 476, 530, 586, 622
 - Kelly 616
 - LAN 467, 499, 631
 - LS 494
 - MKPL-1 530
 - NGP 467, 471, 476, 530, 622
 - N18 603
 - N206 530
 - SH-SY-5Y 582
 - SJNB 530
 - SK-N-AS 467
 - SK-N-BE 447, 463, 467, 471, 499, 530, 576, 627
 - SK-N-FI 530
 - SK-N-SH 520, 616
 - SMS-KCNR 530
 - TR14 530
 - UHG-NP 530
- Chemoresistance 560
- Chemotherapy 568, 572, 606, 612, 616, 642
 - chemoresistance 560
 - in vitro* 576, 616
 - of poor prognostic groups 568, 572, 612, 642
 - taxanes (docetaxel, paclitaxel) 494
 - with MIBG 576, 606
 - with myeloablative therapy 572
- Chromogranin A (CHGA) 447, 557
- Chromosome 12q 520
- Chromosome 14q 505
- Chromosome 17q 530
- Chromosome 1p 505
 - deletion 510, 538, 541, 637
 - detection of 535
 - LOH 541
 - translocation 527, 530, 533
 - 1;17q 523, 530
- Chromosome 2p 520
- Clinical trials 447, 572, 596, 600, 612, 637, 642
- CTP-synthetase inhibition 627
- Cytotoxicity, *in vitro*
 - cyclopentenyl cytosine 627
 - cytostatic drugs 616
 - etoposide 622
 - MIBG 582
 - of taxanes 494
- Differentiation 435, 453
 - calcyclin 499
 - CD44 expression 471, 549
 - CSRC* expression 435
 - effect of growth factors 453
 - effect of Schwann cells 429
 - pancreastatin 557
 - retinoic acid 447, 486
 - S-100 499
- Disseminating disease
 - detection of cells in blood 553
 - genetic alterations 560
- Drug screening 616
- Ferritin 637
- Ganglioneuroma 435, 481, 557
 - CSRC* expression 453
 - pancreastatin release 557
 - somatostatin release 481
 - VIP release 481
- Growth factors—see also IGF 453, 467
- GST—see Chemoresistance
- GTPase activating proteins—see p21^{ras} proteins
- Heterogeneity
 - effect on treatment choice 568
 - genetic subtypes 505
- IGF (Insulin-like growth factors)
- Localised tumours
 - cytogenetics 510
 - pancreastatin 557
- Markers—see individually listed markers (Calcyclin, CD44, Chromogranin A, Chromosomes 1p and 14q, Ferritin, max, *MYCN*, *MDM2*, *MKI*, *NSE*, p21^{ras}, Pancreastatin, S-100, *CSRC*, Somatostatin, Tyrosine hydroxylase, *TRK*, VIP
- max protein 516
- MDM2* 520
 - with *MYCN* amplification 520
- MDR1* (*PGY1*)—see Chemoresistance
- Metastatic disease—see Disseminating disease
- Methylation modifier genes 538
- MIBG (Meta-iodobenzylguanidine) 576, 582, 586, 596, 600, 603, 606
 - effect of catecholamines 586
 - in vitro* efflux 591
 - no-carrier added 576
 - tumour intake 576, 631
 - uptake 576, 586, 603
 - with cisplatin 606
 - with hyperbaric oxygen 596
- MKI* (Mitosis-karyorrhexis index) 458

- Molecular techniques
 - PCR (polymerase chain reaction) 499, 535, 553, 586
 - reverse genomic hybridisation 520
 - YAC screening 527
- MYC*—see *MYCN*
- Myeloablative therapy 572
- MYCN*
 - activation 560
 - amplification 435, 471, 505, 510, 516, 520, 538, 541, 560
 - mycN/max protein complex 516
 - mycN protein 505
 - with CD44 expression 471, 549
 - with *MDM2* amplification 520
- Nerve growth factor receptor—see *TRK*
- Neurofibromin—see p21^{ras} proteins
- NSE (neuron specific enolase) 435, 637
- p21^{ras} proteins 476
- Pancreastatin 557
- Ploidy 505, 510, 541
- Prognosis, factors affecting 505, 510, 541, 637
 - pancreastatin 557
 - see also Markers
 - see also Spontaneous regression
 - therapy 568
- Prognostic groups—see Prognosis, Heterogeneity, Survival rates, Therapy
- PGY*—see Chemoresistance
- Retinoic acid 476, 486
 - effect on differentiation 453, 476, 486
 - effect on gene expression 447, 486
 - effect on p21^{ras} proteins 476
 - RAR 486
 - RXR 486
- S-100
- Schwann cell 541
- Screening 565
- Somatostatin 481
- Spontaneous regression 429
 - cytogenetics 429, 505, 510
- Stage 4 596, 600, 612, 642
- Stage 4S tumours
 - cytogenetics 510
- Survival rates 545, 572, 637
- Taxanes—see Chemotherapy, and Cytotoxicity
- Therapy
 - for prognostic groups 568, 637
 - hyperbaric oxygen 572, 596
 - of poor prognostic groups 572, 596, 600, 642
 - see also Chemotherapy, MIBG, Myeloablative therapy, Bone marrow transplantation, Growth factors
- TRK* 444, 453, 510
 - detection of 444
- Tumour imaging 576, 631
- Tumour suppressor genes—see also Chromosome 1p, *MYCN* 538
- Type I and II GAP—see p21^{ras} proteins
- Tyrosine hydroxylase 553, 586
- Vasoactive intestinal peptide (VIP) 481
- Vitamin A—see Retinoic acid

Author Index

- Alemà, S. 444
 Amann, G. 637
 Ambros, I.M. 429, 510, 637
 Ambros, P.F. 429, 510, 637
 Amler, L.C. 520, 527
 Annicchiarico-Petruzzelli, M. 463
 Atkinson, J.B. 572
 Avigliano, L. 463

 Badal, D. 642
 Bagnulo, S. 612
 Bauer, S. 510
 Beck, D. 467, 471
 Beck, J. 586
 Bénard, J. 560
 Beretta, C. 471
 Beretta Brognara, C. 467
 Berry, P.A. 476
 Berthold, F. 541, 549, 616
 Bick, J. 586
 Bjelfman, C. 435
 Bjellerup, P. 481, 557
 Bodlaender, J.M. 627
 Bossi, G. 447
 Bouvier, R. 545
 Bradbury, F.M. 553
 Brisigotti, M. 499
 Brixy, F. 631
 Brodeur, G. 505
 Bruchelt, G. 586
 Burchill, S.A. 476, 553

 Carli, M. 612
 Caron, H. 538, 600
 Casale, F. 612
 Castel, V. 642
 Castello, M.A. 444
 Cheng, N.C. 530, 538
 Christiansen, H. 541, 549
 Combaret, V. 545
 Cornelissen, J. 582
 Corvi, R. 520, 527
 Cunningham, S. 576

 De Bernardi, B. 612
 De Kraker, J. 596, 600
 De Laurenzi, V. 463
 De Sio, L. 612
 Deb, G. 612
 Delattre, O. 535, 538
 Digiesi, G. 444
 Dominici, C. 444
 Donfrancesco, A. 444, 612

 Elzinga, L. 582
 Emminger, W. 637
 Evans, A.E. 428

 Fabretti, G. 499
 Fagerström, S. 453
 Farina, A. 447

 Favrot, M.C. 545
 Finazzi-Agrò, A. 463
 Fink, F.-M. 510, 637
 Francke, U. 523
 Frappaz, D. 545
 Fridman, W.-H. 631
 Fulda, S. 616

 Gadner, H. 510, 637
 Gaetano, C. 447
 García-Miguel, P. 642
 Gargano, N. 444
 Gaze, M.N. 576
 Gebhardt, S. 586
 Gekeler, V. 586
 Gestblom, C. 453, 458
 Gonzalez, M. 549
 Grienberger, H. 637
 Gross, N. 467, 471

 Haase, G.M. 572
 Handgretinger, R. 520, 568
 Hedborg, F. 435, 453
 Heij, H.A. 600
 Helman, L.J. 447
 Helson, L. 612
 Hero, B. 541
 Hoefnagel, C.A. 596, 600
 Hoehner, J.C. 453, 458
 Höfler, G. 637
 Honer, M. 616
 Horcher, E. 510, 637

 Iavarone, A. 591

 Jackson, D. 471
 Johansson, I. 453

 Kerbel, R. 637
 Kogner, P. 481, 557
 Kovar, H. 510
 Kuznicki, J. 499

 Ladenstein, R. 510, 637
 Lampert, F. 541, 549
 Larsson, U. 453
 Lasorella, A. 591, 606
 Lasset, C. 545
 Laureys, G. 523, 530, 538
 Lavenius, E. 453
 Le Paslier, D. 527
 Lewis, I.J. 476, 553
 Lode, H.N. 586
 Lovat, P.E. 486
 Lowis, S.P. 622
 Luegmayer, A. 510

 Magdelénat, H. 535
 Mairs, R.J. 576
 Malcolm, A.J. 486
 Mancini, A. 606, 612

 Mann, G. 510
 Manni, I. 447
 Massimo, L. 499
 Mastrangelo, R. 606
 Mastrangelo, S. 494, 591, 606, 616
 Matthay, K.K. 572
 Mazzocco, K. 499
 McDowell, H. 444
 Melero, C. 642
 Melino, G. 463
 Menke-Moellers, I. 616
 Michon, J. 535, 631
 Miyoshi, I. 603
 Modesto, C. 612
 Molina, J. 642
 Moutel, S. 631
 Mutz, I. 510, 637

 Nänberg, E. 453
 Natali, P.G. 444
 Navajas, A. 642
 Navarro, S. 642
 Newell, D.R. 622
 Nicotra, M.R. 444
 Niethammer, D. 568, 586
 Nigro, M. 612

 O'Donoghue, J.A. 576
 O'Leary, M.C. 572
 Opdenakker, G. 523, 530
 Ørtoft, E. 453
 Owens, J. 576

 Padula, A. 444
 Pählman, S. 435, 453, 458
 Pearson, A.D.J. 427, 486, 622
 Perdureau, B. 631
 Perruisseau, G. 471
 Peter, M. 535
 Philip, T. 545
 Piaggio, G. 447
 Praml, C. 527
 Prinz, D. 510
 Puggioni, P. 494

 Ramsay, N.K. 572
 Rebillard, A.-C. 545
 Redfern, C.P.F. 486
 Reynolds, C.P. 572
 Riccardi, A. 494
 Riccardi, R. 494, 591, 606
 Rufini, V. 606
 Ruiz-Jimenez, J.I. 642
 Rumi, C. 494
 Russell, J. 576
 Rutgers, M. 603

 Sacchi, A. 447
 Sahin, K. 541
 Sandstedt, B. 435
 Savelyeva, S. 520, 527

Savini, I. 463
 Scaruffi, P. 499
 Schilling, F.H. 510, 565
 Schleiermacher, G. 535
 Schmitt, K. 637
 Schwab, M. 427, 516, 520, 527
 Seeger, R.C. 572
 Seitz, G. 586
 Selby, P. 553
 Servidei, T. 494, 591
 Slater, R. 538
 Slingerland, R.J. 627
 Soddu, S. 447
 Söderholm, H. 453
 Sparén, P. 435
 Speleman, F. 523, 530, 538
 Stram, D.O. 572
 Strehl, I.M. 510

Svensson, T. 557
 Takeuchi, S. 603
 Teillaud, J.-L. 631
 Terpe, H.-J. 541, 549
 Theodorsson, E. 481, 557
 Thiesse, P. 545
 Thomas, G. 535
 Tiel-van Buul, M.M.C. 596
 Tonini, G.P. 499
 Tornesello, A. 494, 606
 Treuner, J. 565
 Troncone, L. 606
 Tytgat, G.A.M. 603
 Urban, C. 510, 637
 Vaidyanathan, G. 576
 Valdés Olmos, R.A. 600

Van den Bogert, C. 582
 van der Drift, P. 523, 538
 Van der Kleij, A.J. 596
 Van Gennip, A.H. 582, 596, 627
 Van Kuilenburg, A.B.P. 582, 627
 Van Roy, N. 523, 530, 538
 Versteeg, R. 523, 530, 538
 Villablanca, J. 572
 Voûte, P.A. 538, 582, 596, 600, 603, 627
 Wanders, R.J.A. 582
 Wenzel, A. 516
 Westerveld, A. 538
 Zalutsky, M.R. 576
 Zoubek, A. 637
 Zsiros, J. 600
 Zucker, J.-M. 535